Cribstone Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cribstone Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.06M	Buy	12,799 +506	+4%	+$41K	0.62%	50
2022 Q3	$975K	Sell	12,293 -1,643	-12%	-$139K	0.6%	48
2022 Q2	$1.03M	Buy	13,936 +787	+6%	+$59.1K	0.64%	43
2022 Q1	$1.18M	Buy	13,149 +3,959	+43%	+$366K	0.65%	45
2021 Q4	$1.03M	Buy	9,190 +859	+10%	+$104K	0.57%	47
2021 Q3	$1.05M	Buy	8,331 +1,495	+22%	+$193K	0.62%	42
2021 Q2	$926K	Buy	6,836 +245	+4%	+$32.2K	0.56%	48
2021 Q1	$894K	Buy	6,591 +32	+0.5%	+$4.79K	0.59%	48
2020 Q4	$923K	Buy	6,559 +16	+0.2%	+$2.05K	0.63%	42
2020 Q3	$729K	Sell	6,543 -187	-3%	-$21K	0.6%	48
2020 Q2	$753K	Buy	6,730 +190	+3%	+$18.7K	0.62%	51
2020 Q1	$506K	Buy	6,540 +1,714	+36%	+$152K	0.54%	53
2019 Q4	$459K	Sell	4,826 -1,440	-23%	-$125K	0.41%	60
2019 Q3	$478K	Sell	6,266 -998	-14%	-$82.9K	0.29%	69
2019 Q2	$637K	Buy	7,264 +1,798	+33%	+$153K	0.35%	64
2019 Q1	$495K	Buy	+5,466	New	+$465K	0.26%	75

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Cribstone Capital Management's XBI Position: Q4 2022 in Review

Cribstone Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 4.1% in Q4 2022, buying an estimated $41K and bringing the position to 12,799 shares worth $1.06M. The position accounts for 0.62% of the portfolio, ranked #50.

Cribstone Capital Management first reported a position in XBI in Q1 2019 and has held it in 16 quarters since. The position peaked at $1.18M in Q1 2022. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

Cribstone Capital Management held 12,799 shares of State Street SPDR S&P Biotech ETF worth $1.06M as of Q4 2022.
Cribstone Capital Management bought 506 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $41K.
State Street SPDR S&P Biotech ETF made up 0.62% of Cribstone Capital Management's portfolio in Q4 2022, its #50 holding.
Cribstone Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and has held it in 16 quarters since.
Cribstone Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.18M in Q1 2022.
746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Cribstone Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.